Articles by Gary L. Kreps, PhD
Marketing Off-Label Uses: Shady Practices Within a Gray Market
ByCathy L. Melvin, PhD, MPH,Timothy S. Carey, MD, MPH,John M. Oldham, MD,John W. Williams Jr, MD,Francine Goodman, PharmD,Thomas R. Linden, MD,W. Douglas Evans, PhD,Gary L. Kreps, PhD,Leah M. Ranney, PhD For pharmaceutical companies, off-label use of a drug represents a substantial “gray market,” to which the company is unable to sell their product directly, yet may be a significant revenue stream. Some drugs have been used more for off-label purposes than for originally approved indications.1
